Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.87 |
| ▸ | PRKCA | P17252 | 4/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.74 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.69 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.69 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.68 |
| ▸ | TLR2 | O60603 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecanoate SCHEMBL28600376 | 1.00 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Dodecanoate SCHEMBL30736803 | 1.00 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Stearic Acid SCHEMBL17144666 | 1.00 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL29626993 | 1.00 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Tricaprilin SCHEMBL7061899 | 1.00 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Nonanoate SCHEMBL25181546 | 1.00 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Palmitic Acid SCHEMBL2788109 | 1.00 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Tripalmitin SCHEMBL30991684 | 1.00 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| SCHEMBL31112712 | 1.00 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ | |
| Tripalmitin SCHEMBL29220029 | 1.00 | ALDH1A1 (0.87) | ALDH1A1LMNAPRKCAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023086514-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-107879960-B | Lipids and lipid compositions for delivery of active ingredients | 诺华股份有限公司 | 2021-06-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295081-A1 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | NSUN3, POLRMT, NPC1L1 | ALDH1A1 3327/4885LMNA 1041/4885PRKCA 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.